ESC Gold Medals and President Awards

ESC Gold Medal 2024

Karin Sipido (Leuven, Belgium)

Karin Sipido, MD, PhD, is Emeritus Professor at the Department of Cardiovascular Sciences, KU Leuven. She trained in internal medicine and cardiology, and continued a career in basic and translational research, with focus on cellular mechanisms of heart failure and arrhythmias, in an interdisciplinary collaboration. She is an elected member of the Academia Europaea, Fellow of the International Society for Heart Research, and Fellow of the ESC. She was Editor-in Chief of Cardiovascular Research and serves on the editorial board of leading international journals. She takes an active interest in research policy, serving in various positions at KU Leuven, at European and international level. She has chaired the European Commission’s Scientific Panel for Health, and she is member of the Scientific Advisory Board of ORE, the European Commission’s Open Research Platform. She acts as advisor to the ESC’s Advocacy Committee. She is member of the Ethics Committee Research at UZ Leuven.

Milton Packer (Dallas, USA)

Milton Packer is the Distinguished Scholar in Cardiovascular Science at Baylor University Medical Center at Dallas and Visiting Professor at Imperial College, London. He is an internationally recognized clinical investigator who has made many seminal contributions to the field of heart failure, both in understanding its mechanisms and defining its rational management. His work has spanned more than 40 years and has established the cornerstone of the current modern treatments for heart failure, including ACE inhibitors, beta-blockers, angiotensin neprilysin inhibitors and SGLT2 inhibitors. He proposed the neurohormonal hypothesis of heart failure in 1992. He has led 20 large-scale international trials of novel interventions for heart failure and has received many international awards in recognition of his achievements. His column on MedPage Today received the Jesse H. Neal Award, Best Commentary/Blog; the award is equivalent to the Pulitzer Prize for business journalism.

Peter J Schwartz (Milan, Italy)

Peter J. Schwartz, MD is the the Director of the Center for Cardiac Arrhythmias of Genetic Origin and of the Laboratory of Cardiovascular Genetics at the Istituto Auxologico Italiano, IRCCS, Milan, Italy. From 1995 to 2013, he was Professor and Chairman of Cardiology at the University of Pavia, Italy. His major areas of interest and expertise are the relationship between the autonomic nervous system and life-threatening arrhythmias, the long QT syndrome (LQTS), and risk stratification for sudden death. He received numerous prestigious awards, including named lectures. Since September 2020, Prof. Schwartz is the Associate Editor for Genetics of the European Heart Journal. Since January 2023, he is the Associate Editor for Sudden Cardiac Death and Risk Stratification of Europace. He is the author of about 1600 publications.

ESC President Award 2024

Eva Prescott (Copenhagen, Denmark)

Professor Prescott heads the Centre for Cardiovascular Research at Bispebjerg Frederiksberg University Hospital, Copenhagen. Her main research areas are in angina pectoris, cardiac rehabilitation and epidemiological studies of precursors of CVD, including gender differences and psychosocial factors and she has published more than 380 papers. Professor Prescott has initiated and participated in several national and international randomised trials mainly in stable coronary artery disease and rehabilitation. She is also the PI of iPOWER, the largest prospective multicenter study of women with angina and no obstructive epicardial disease focusing on the role of microvascular dysfunction, and of the Danish nationwide DANBLOCK trial. Professor Prescott has served the congress programme committee and several ESC Guidelines, has chaired the ESC working group on prevention, epidemiology and population science and is currently chair of the Clinical Practice Guidelines of the ESC.

Hector Bueno (Madrid, Spain)

ESC Gold Medal 2023

Arthur Wilde (Amsterdam, The Netherlands)

Arthur A.M. Wilde, born in 1956, got his M.D. at the University of Amsterdam in 1983. After his Ph.D. in 1988, he started his Fellowship training in Cardiology at the Academic Medical Centre, and was registered as such in 1994. Afterwards he specialized in clinical electrophysiology at the Academic Hospital Utrecht. From the Netherlands Heart Association he was awarded a grant as Clinical Established Investigator for five years. In 1999, he became head of the Laboratory of Experimental Cardiology, and in 2003 head of the Department of Clinical and Experimental Cardiology (Academic Medical Centre). He published over 550 SCI papers with, in recent years, a major focus on different aspects of inherited arrhythmia syndromes. In more recent years also genetic factors contributing to sudden cardiac death in the general population became a focus. In 2011 he was appointed as member of the Dutch Academy of Science and in 2012 he received the HRS Distinguished Investigator award.

Silvia Giuliana Priori (Pavia, Italy)

Silvia G Priori, M.D., PhD was born in Torino in 1960. She graduated in Medicine in 1986 at the University of Milan (Italy) and she became specialist in Cardiology in 1990. In 1995 she obtained a PhD in Cardiac Pathophysiology. Currently, she is Full Professor of Cardiology and Director of Cardiology Specialization School at the University of Pavia (Italy), Head of the Molecular Cardiology Unit and Director of General Medicine III Unit (April 2018-present) at the IRCCS Istituti Clinici Scientifici Maugeri SpA SB of Pavia (Ex IRCCS Fondazione S Maugeri). Dr. Priori is also Director of the Cardiovascular Genetics Program, at the Centro National de Investigaciones Cardiovasculares, Carlos III (CNIC), Madrid, Spain and Vice-President of the ESC. Professor Priori has been primarily involved in the study of the genetic mechanisms of the inherited arrhythmogenic syndromes and Gene therapy.

Bertram Pitt (Ann Arbor, USA)

Bertram Pitt was born on 27 April 1932 in New York . He received a BA degree from Cornell University in 1953 and his MD from the University of Basel in 1959 . He trained in cardiology at the Johns Hopkins University School of Medicine and remained there until 1977 when he went to the University of Michigan as professor of medicine and director of the division of cardiology, where he is currently professor emeritus . He has received lifetime achievement awards from ESC HF and HFSA as well as the James B Herrick award from the AHA. He has been principal or co-principal investigator of a number of clinical trials including SOLVD, ELITE 1&2 , RALES, EPHESUS, EMPHASIS- HF, TOPCAT, FIGARO and Block-CKD . He has published over 750 peer reviewed articles. He is married to Elaine Pitt MD, a psychiatrist, and has 3 children one of whom Geoffrey Pitt MD is director of cardiovascular research at Weil Cornell Medical College.

ESC President Award 2023

Chris Plummer (Newcastle Upon Tyne, UK)

Chris Plummer is a cardiologist and Chief Clinical Information Officer at Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, UK. He has chaired the European Examination in Core Cardiology since 2017. During this time, the number of candidates has more than doubled from 384 to 973 from over 30 countries, and moved successfully to on-line delivery. It has developed a very popular on-line introductory module and mock exam, co-written by trainees and senior cardiologists. He is Vice-President of the Cardiology Section of the Union of European Medical Specialists, ESC Education Committee Certification, Exams and EECC Coordinator, and a Nucleus Member of the ESC Council of Cardio-Oncology. His interests include device therapy, cardio-oncology, informatics, and education. He is a strong advocate of collaboration between all healthcare professionals, in the development and delivery of new treatments, and the use of digital technologies to improve patient safety.

Gunnar Olsson (Vastra Frolunda, Sweden)

Gunnar Olsson, FESC, is a Board-Certified physician, holding a specialist degree in Cardiology and Internal Medicine. He is an Honorary doctor in Medicine at Gothenburg University since 2004. He worked in AstraZenenca for 25 years in various senior positions. He has a long-standing involvement within the ESC, being one of the “founding fathers”, in 2001, of the Cardiovascular Round Table (CRT) activities, including ESC-industry high level strategic discussions on future needs in the area of Cardiovascular medicine. Following his retirement from AstraZeneca, he was invited to become an ESC Board member as the first advisor to the board and management group (2014-2020). Since the latter part of 2020 he is a member of the Audit Committee of the ESC. Prof. Olsson contributed and committed for more than 20 years to the ESC.

ESC Gold Medal 2022

Issei Komuro (Tokyo, Japan)

Dr. Komuro was graduated from The University of Tokyo in 1982 and after clinical residency, he has started research on mechanisms of cardiac hypertrophy and heart failure. He has reported that angiotensin II type 1 receptor is involved in mechanical stress-induced cardiac hypertrophy and has recently reported novel mechanisms of heart failure such as ischemia, inflammation and aging. He has also studied cardiac development and has isolated cardiac specific homeobox protein Nkx2.5. He has published more than 800 papers on peer-review journals including Natute, Cell and Nature Medicine.

Marie-Claude Morice (Massy, France)

Dr Marie-Claude Morice studied at the University of Medicine in Paris where she obtained her medical degree in 1973 and her Diploma in Specialized Cardiology Studies in 1975.
In 1986, she was appointed Head of the Interventional Cardiology Department of the CCN, the  2nd largest PCI center in France in 1990.
Since 1995, she has been the Head of Interventional Cardiology at the Institut Cardiovasculaire Paris (Ramsay Générale de Santé) the highest-volume PCI centers in the Greater Paris Area.
Dr Morice is a Fellow of the European Society of Cardiology and the American College of Cardiology and Honorary Professor of the Universidad Del Salvador in Buenos Aires. 
She is regularly invited as a guest lecturer and chairperson at all major international Cardiology scientific sessions of the AHA, ACC and ESC as well as guest faculty and live case operator in all prominent Interventional Cardiology courses (TCT, TCTAP, TOPIC, CIT, SUMMIT, EuroPCR) in Europe, North and South America and Asia and a board member and Senior Consulting Adviser of EuroPCR. She is a co-editor for EuroIntervention and an invited reviewer for the Lancet, the NEJM, JAMA, Circulation, JACC, EHJ and others. 
Dr Morice has been involved in multiple clinical research activities over the past 20 years resulting in more than 250 peer-reviewed publications.  She was voted Best Clinical Researcher in 1995 (Erasmus) and Cardiologist of the year in 1997. She was the co-founder of the French study group ‘Coronary Stenting Without Coumadin’, the Principal Investigator of the Ravel Trial, the Reality Study and the co PI of the  Syntax Trial in charge of the Left Main publications. 
She is the President and Medical Director of the European Center for Cardiovascular Research (CERC) which was founded in 2008, CERC is now a reputable CRO conducting breakthrough CV trials worldwide. Dr. Morice has been a member of the Scientific Advisory Council of the Coeur & Recherche Foundation since 2018.
In 2013 Dr Morice  was designated Best  Interventional Cardiologist in France by the French magazine  Capital, and in 2014 she received the CHIEN award during ASIA PCR and the  Geoffrey O. Hartzler Master Operator Award at TCT 2014 for her career achievements.
Dr. Morice is a member of the executive committee of the Leaders Free, Compare Absorb and Senior trials. She has been a member of the Tokyo Valve Board of Directors since 2016, and of the PCR Clinical Research Course Board of Directors from 2015 to 2020. 
She gave the Gruntzig Lecture during the 2017 Scientific Sessions of the ESC. Dr. Morice is co-organizer and member of the expert team of the ARC HBR initiative. Dr Morice is part of the ARC funding members. She received the Gruntzig Award at EuroPCR 2021.

Göran K Hansson (Stockholm, Sweden)

Professor Goran Hansson is mainly known for his discoveries concerning the role of inflammation in atherosclerosis. He received his MD and PhD from Gothenburg University in Sweden, was a Fogarty postdoctoral fellow at the University of Washington in Seattle, is board certified in laboratory medicine, and became professor of cell biology at Gothenburg University in 1994. Since 1995, he is professor of cardiovascular research at Karolinska Institute and Karolinska University Hospital in Stockholm. He has been visiting professor at Harvard Medical School and Secretary General of the Royal Swedish Academy of Sciences. Recognitions include the first Anitschkow Prize from European Atherosclerosis Society, awards from the European Society of Cardiology and American Heart Association, and honorary academic degrees.

2022 ESC President Award

Tiny Jaarsma (Linköping, Sweden)

Professor Tiny Jaarsma is a full professor of Nursing at Linköping University in Sweden, were she lives with her family. She is also employed part time as a full professor of Nursing Science in the Julius Center, University Medical Center Utrecht, the Netherlands. 
Her research focuses on the consequences of heart failure for patients and their families and developing and testing interventions to enhance their self-care. She is the editor-in chief of the European Journal of Cardiovascular Nursing. Professional activities include membership of national and international committees and guidelines (ESC, AHA), reviewer and member of editorial boards of peer-reviewed journals. 

Steen Dalby Kristensen (Aarhus, Denmark)

Department of Cardiology, Aarhus University Hospital, Denmark and Institute of Clinical Medicine, Health, Aarhus University, Denmark. Born in Aarhus, Denmark 1955.  Married to Inge, two children.

Cand. med. (MD) Aarhus University 1981. Doctoral thesis (DMSc) Aarhus University 1992: 'The platelet-vessel wall interaction in experimental atherosclerosis and ischaemic heart disease.

Education and employment:

Clinical training  in internal medicine and cardiology in Aalborg, Viborg and Aarhus. Research and clinical fellowship in Sheffield and Kings College Hospital, London, UK. Specialist in Cardiology and Internal Medicine 1995. 1995: Consultant Interventional Cardiologist, Department of Cardiology, Aarhus University Hospital - 2000 - 2006: Head of Department of Cardiology, Aarhus University Hospital. 2006-2011: Associate Professor Department of Cardiology, Aarhus University Hospital. 2011: Full professor, Department of Cardiology, Aarhus University Hospital.

Scientific and clinical interests:

Thrombosis and anti-thrombotic treatment. Coronary artery disease and acute cardiac care. Percutaneous coronary interventions.

Author and co-author of more than 365 scientific papers and 17 book chapters. Editor of 5 books including textbooks in 'Antithrombotic Therapy'. Editor of European Heart Journal, Thrombosis and Haemostasis and European Heart Journal: Acute Cardiovascular Care.

Chair of international research committees for evaluation of scientific applications in Germany and Spain. Evaluator of grants in Sweden, Norway, Italy, Germany, Spain, Finland and Denmark. Have given numerous talks at international meetings (invited speaker in more than 40 different countries). Supervisor of 12 PhD students and 15 research year students.

Have for many years been conducting and leading investigator initiated trials and have been investigator and steering committee member in international multicenter trials.

Voluntary work in the ESC: Nucleus member of ESC WG Thrombosis 1998. Secretary/treasurer 2000- 2002, vice-chairman 2002-2004 and Chairman of the Working Group on Thrombosis in European Society of Cardiology 2004-2006. ESC Education Committee 2004-2006. ESC Congress Programme Committee 2006 -2020. Editor-in-chief of 'ESC TV' 2014-2018. ESC Committee for Practice Guidelines 2006-2008. Councillor of the ESC Board 2006-2008. Chairman of the ESC Credential Committee 2008 - 2010. ESC EU Committee for Regulatory Affairs 2008 - 2010. Vice President for ESC 2008 - 2010 (National Societies and Fellowships). Chairman EAPCI/ESC Committee 2010 - 2012: Stent For Life (implementation of Primary PCI and STEMI networks in ESC countries). ESC Secretary/Treasurer 2012 - 2014. ESC Audit Committee 2012 – 2014. ESC ex-Officio Board member 2014-2020. ESC Ethics Committee 2018. ESC Declaration of Interest Committee 2018. ESC Press Committee Chair 2014-2018. ESC Communication Committee Chair 2018-2020. ESC Press Lead 2020 – 2022.

National volunteer work: President of Danish association of Young Cardiologists 1991-95. Advisor/and evaluator for the Danish Heart Foundation, Danish National Board of Health and several other national bodies. Member of the Board of Danish Society of Cardiology 2018. President of the Danish Society of Cardiology 2020-2022. 

Interests beyond cardiology: Family and friends, chess, cooking, skiing.

Adam Timmis (London, UK)

Chair European Heart Health Institute

Adam Timmis is Emeritus Professor of Clinical Cardiology at Queen Mary University London and a recipient of the British Cardiovascular Society’s Mackenzie Medal for outstanding service to UK cardiology. He graduated from Cambridge University and trained in cardiology at Massachusetts General and Guys Hospitals before moving to the Barts Heart Centre in London. He was former Editor of Heart and chaired NICE guideline groups on investigation of stable chest pain and management of angina.  His cardiovascular outcomes research was originally based on local data collections in east London before it moved on to the UK’s cardiovascular registries which, through linkage with primary care records, have provided a national perspective on the patient journey through a range of cardiovascular phenotypes. He is now founding Editor-in-Chief of European Heart Journal-Quality of Care and Clinical Outcomes (EHJ-QCCO) and chairs the European Heart Health Institute (EHHI) in Brussels where his work is focused on the ESC Atlas project, developed by Professor Panos Vardas, with oversight of the biennial reports of ESC cardiovascular statistics that are published in the European Heart Journal.

ESC Gold Medal 2021

Renu Virmani (Gaithersburg, USA)

Renu Virmani, M.D., F.A.C.C. is an internationally renowned cardiovascular pathologist, recognized as a leading researcher in the field of cardiovascular disease treatments and presently serves as the President of CVPath Institute, which she founded in 2005. Dr. Virmani received her M.D. from Lady Hardinge Medical College, Delhi University, New Delhi, India.
Lecturing at scientific meetings all over the world, Dr. Virmani has delivered more than 800 presentations. She has authored or co-authored over 800 publications in peer-reviewed journals covering atherosclerosis, vulnerable plaque, stents and other cardiovascular diseases; she has edited seven books, written more than 100 book chapters and is also a manuscript reviewer for many top scientific journals.
Among numerous outstanding honors and awards, Dr. Virmani has delivered the Laennec Clinician/Educator Lecture Award for the American Heart Association in 2010; she has received the TCT Career Achievement Award from the Cardiovascular Research Foundation in 2012; the ICI Innovations in Cardiovascular Interventions Award in 2013; the Female Luminary Award from the Society for Cardiovascular Angiography and Interventions Foundation in 2016; she received an honorary degree from the University of Antwerp, Belgium as well as many other honorary awards including from the European Society of Cardiology and EuroPCR. Dr. Virmani has recently won the TCTAP “11th Master of Masters 2021 Award.”
Dr. Virmani is currently a Clinical Professor in the Department of Pathology at Georgetown University; University of Maryland-Baltimore; George Washington University; and Vanderbilt University. From 1984 until 2004, she was Chairperson of the Department of Cardiovascular Pathology of the Armed Forces Institute of Pathology. Dr. Virmani is a member of the American Heart Association, the U.S. and Canadian Academy of Pathology, and is a Fellow of the American College of Cardiology.

Read the ESC Congress News article

Nilesh Samani (Leicester, UK)

Current posts
2016- Medical Director, British Heart Foundation
1997- Professor of Cardiology, University of Leicester (2003-2016, BHF Professor)
1997- Honorary Consultant Cardiologist, University Hospitals of Leicester NHS Trust
Previous posts
2009-17 Director of NIHR Leicester Biomedical Research Unit in Cardiovascular Disease
2003-16 Head of Department of Cardiovascular Sciences, University of Leicester
1993-97 Senior Lecturer in Cardiology, University of Leicester
1988-93 Lecturer in Cardiology, University of Leicester
1985-88 MRC Clinical Training Fellow, Dept. of Biochemistry, University of Leicester
1984-85 Registrar in Medicine, Leicester Royal Infirmary
1982-84 Senior House Officer in Medicine: Royal Postgraduate Medical School Hammersmith
Hospital; Guy’s Renal Unit; National Hospital for Nervous Diseases, Queen’s Square
1981-82 House Officer in Medicine and Surgery, Leicester Royal Infirmary

I have published >540 original papers with >78,000 citations and have an h-index (Scopus) of 124. These include 15 papers in Nature, 51 in Nature Genetics, 1 in Science, 5 in NEJM, 15 in Lancet, 3 in JAMA, 6 in PNAS, 13 in Circulation,16 in European Heart Journal and 20 in JACC. Between 2014-2018, I was included in the list of most highly cited researchers compiled by Thomson Reuters.
 I have supervised/co-supervised over 30 PhD and MD students and mentored many colleagues who have progressed to chairs and established their own research groups.
I have been awarded >£30 million research funding with programmatic support from all major UK biomedical funders (MRC, Wellcome, BHF, NIHR) as well as international funders (EU, Leducq).
I have led, chaired or participated in multiple national and international research consortia, including EURHYPGEN (PI), Cardiogenics (Co-PI), CARDIoGRAMPlusC4D (Chair), WTCCC (co-I), ENGAGE, and BIOSTAT-CHF (WP Lead).

Until my appointment as BHF Medical Director, I had maintained a full clinical practice throughout my career, including interventional cardiology and on-call and was awarded a NHS Platinum Excellence award in 2010 (renewed in 2015). I still undertake one clinic a week.
In 2002, together with members of the local community, I established Heartsearch, a charity whose principle aim is to raise awareness of heart disease, its symptoms and risk factors. The charity, through its volunteers, organizes regular open public meetings, especially in socioeconomically deprived areas of Leicester, often attended by hundreds of people, where people receive information and advice from health professionals and have the opportunity to have their risk factors checked.
In 2008, I was appointed as a Deputy Lieutenant of Leicestershire. Working under the Lord Lieutenant as part of the Leicestershire Lieutenancy, the role offers me the opportunity to undertake civic functions such as citizenship ceremonies and to provide support and visibility to local charity and volunteer organisations.

Read the ESC Congress News article

Akira Endo (Tokyo, Japan)

March 1957 : Bachelor of Agriculture from Tohoku University Faculty of Agriculture, Sendai, Japan
April 1957 : Research Fellow, Sankyo Co., Ltd., Tokyo, Japan
Sept. 1966 : Ph.D. in Biochemistry from Tohoku University
Research Associate, Department of Molecular Biology (Prof. Dr. B.L. Horecker), Albert Einstein College of Medicine, New York, U.S.A.
Aug. 1968 : Research Fellow, Sankyo Co., Ltd., Tokyo, Japan
Apr. 1969 : Senior Research Fellow, Sankyo, Co., Ltd.
Jan. 1979 : Associate Professor, Tokyo Noko University Faculty of Agriculture, Fuchu, Tokyo, Japan
Dec. 1986 : Professor, Tokyo Noko University Faculty of Agriculture
Apr. 1997 : Emeritus Professor, Tokyo Noko University (retired). Chairman, Biopharm Research Laboratories, Inc., Kokubunji, Tokyo, Japan

Honors:

Oct. 1987 : Heinrich Wieland Prize (Germany)
Mar. 1988 : Torey Prize for Science and Technology (Japan)
May 2000 : Warren Alpert Foundation Prize (USA)
Apr. 2006: Japan Ptize(Japan)
Nov. 2006: Massry Prize(USA)
Sep. 2008: Lasker~Debakey Clinical Medical Research Award

Read the ESC Congress News article

ESC Gold Medal 2020

Kári Stefánsson (Reykjavik, IS)

Kári Stefánsson, M.D., Dr. Med. is founder and CEO of Reykjavik-based deCODE genetics. In Iceland he has pioneered the use of population-scale genetics to understand variation in the sequence of the human genome. His work, published in more than 600 scientific papers, has focused on how genomic diversity is generated and on the discovery of sequence variants impacting susceptibility to common diseases. The population approach he has advanced in Iceland has served as the model for national genome projects around the world and contributed to the realization of several aspects of precision medicine, including to the discovery and development of therapeutic targets and compounds for Amgen. Prior to founding deCODE in 1996 he was professor of neurology, neuropathology and neuroscience at Harvard and had previously held faculty positions in neurology, neuropathology and neurosciences at the University of Chicago, from 1983-1993.

Dr. Stefansson has received some of the highest honors in biomedical research and genetics, including the including the Sackler Lecture at MIT, the European Society of Human Genetics Award, the Anders Jahre Award, the American Alzheimer’s Association’s Inge Grundke-Iqbal Award, the Federation of European Biomedical Societies’ Sir Hans Krebs Medal, and the American Society of Human Genetics (ASHG) William Allan Award. His work has been recognized by major international publications and bodies including Time, Newsweek, Forbes, BusinessWeek and the World Economic Forum. He holds Iceland's highest honor, the Order of the Falcon, and in 2019 was elected the first president of the Nordic Society of Human Genetics and Precision Medicine.

 Watch the video

Stefanie Dimmeler (Frankfurt, DE)

Dr. Dimmeler received her undergraduate, graduate, and Ph.D. degree from the University of Konstanz in Konstanz (Germany). She then completed a fellowship in Experimental Surgery at the University of Cologne and in Molecular Cardiology at the University of Frankfurt (Germany). She is Professor of Experimental Medicine (since 2001) and Director of the Institute of Cardiovascular Regeneration, Center for Molecular Medicine at the University of Frankfurt since 2008. She is author of more than 300 peer-reviewed papers, published in highly qualified journals. Her global impact factor (IF) is higher than 1000 and her h-index is 125. In the last years, she has been invited as a speaker in more than 300 national and international meetings and seminars and has presented various keynote lectures. She received several awards including the Award of the German Heart Foundation in 1998, the Frankel-Award of the German Cardiac Society in 2000, the Alfred Krupp Award 2002, the Leibniz Award 2005, the Award of the Jung Foundation 2007 and the FEBS award 2006. She presented the prestigious George E. Brown Memorial Lecture at the Scientific Sessions of the AHA in 2005, the Basic Science Lecture of the European Society of Cardiology in 2006. She received the Science4life award, the GlaxoSmithKline Award and the Madrid Award for Stem Cell Therapy in 2014 and as well in 2017 the Willi-Pitzer Award. In 2015 she presented the Thomas W. Smith Memorial Lecture at the Scientific Sessions of the AHA and in 2016 the Michael Oliver Memorial Lecture at the BAS Autumn Meeting as well as the Paul Dudley White Lecture at the Scientific Sessions of the AHA. She also was among the Thomson Reuters Highly Cited Researcher 2014 and 2015. She was chief editor of “EMBO Molecular Medicine” and associated editor of the “European Heart Journal”. She is associated editor of “Circulation Research”. Since 2017 she is Member of the German Academy for Science Leopoldina and in 2018 she received the Selby Travelling Fellowship of the Australian Academy of Science. From 2020 on she is Member on the BCVS Specialty Conference Program Committee of the Council on Basic Cardiovascular Sciences. As well she is spokesperson of the “Excellence Cluster Cardio-Pulmonary System” (ECCPS), a translational research centre in the field of vascular and parenchymal heart and lung diseases, funded by the German Research Foundation and also spokesperson of the “Cardiopulmonary Institute” (CPI) which is funded by the Excellence Strategy Program of the German Research Foundation. From 2021 on she is also spokesperson of the German Center for Cardiovascular Research (DZHK). She also received two Advanced Investigator Grants by the European Research Community (ERC).

Her group elucidates the basic mechanisms underlying cardiovascular disease and vessel growth with the aim to develop new cellular and pharmacological therapies for improving the treatment of cardiovascular disease. Ongoing research focuses on epigenetic mechanisms that control cardiovascular repair, specifically non-coding RNAs.

 Watch the video

John McMurray (Glasgow, GB)

Prof McMurray, BSC (Hons), MB ChB (Hons), MD, FRCP, FESC, FACC, FAHA, FRSE, FMedSci, OBE, is currently Professor of Medical Cardiology and Deputy Director (Clinical) of the Institute of Cardiovascular and Medical Sciences and honorary Consultant Cardiologist at the Queen Elizabeth University Hospital, Glasgow.

Prof McMurray’s primary research interests are in heart failure and the cardiovascular consequences of diabetes and chronic kidney disease, with a focus on clinical trials. He is, or was, the principal investigator, member of the executive committee or steering committee member for several large trials in his areas of interest including CHARM-Added, EMPHASIS-HF, PARADIGM-HF and DAPA-HF.

Professor McMurray served as the inaugural Eugene Braunwald Scholar in Cardiovascular Disease at the Brigham and Women’s Hospital, Boston, and visiting Professor of Medicine, Harvard University, Boston, Massachusetts USA 2010/2011. He is a Past-President of the Heart Failure Association of the ESC.
He is a Highly Cited Researcher and has a H-index of 195.

He has won several awards, including the Stokes Medal of the Irish Cardiac Society. In June 2015, Professor John McMurray and Professor Salim Yusuf (McMaster University, Hamilton Ontario, Canada) were jointly awarded the 8th Arrigo Recordati International Prize for Scientific Research (for outstanding contributions in secondary prevention and risk reduction strategies in patients with cardiovascular diseases). Prof McMurray is the recipient of the Mackenzie Medal, which is awarded by the British Cardiovascular Society in recognition of outstanding service to British Cardiology. He is also the recipient of the Louis and Artur Lucian Award for Research in Circulatory Diseases, which is awarded each year by McGill University, Montreal. This international award recognises outstanding research in the field of circulatory diseases by a scientific investigator, or group of investigators, whose contribution to knowledge in this field is deemed worthy of special recognition. Professor McMurray was awarded an OBE in 2019 by Her Majesty The Queen, in recognition of his services to cardiovascular research.

 Watch the video

ESC Gold Medal 2019

Mariell Jessup MD

Dr. Jessup is Chief Science and Medical Officer of the American Heart Association and an Emeritus Professor of Medicine at the University of Pennsylvania School of Medicine. She has spent her career in the investigation and management of patients with heart failure.
Dr. Jessup has been a member of the committee for ACC/AHA Guidelines for the Management of Heart Failure since 2001. She served on the European Society of Cardiology’s Heart Failure Guideline writing committee as well. She has served as the Chair of the American Board of Internal Medicine’s (ABIM) Cardiovascular Board, and for two years as the Chair of the Committee for Scientific Sessions Program of the AHA. She was a member of the Board of Directors of the national AHA, and President from 2013-2014.. She completed a 4-year term on the Residency Review Committee-Internal Medicine of the ACGME, and a 6-year term on the ABIM’s Cardiovascular Board. She joined the Board of the Advanced Heart Failure and Transplant cardiology secondary subspecialty, and became Chair for two years. She was the inaugural Chief Scientific Officer of the Leducq Foundation from January 2017 through August of 2018, before moving to the American Heart Association role.

 Watch the video

Hugo A Katus

Hugo A Katus is Professor of Internal Medicine, Director of the Department of Internal Medicine III (Cardiology, Angiology, Pneumology) and Head of Internal Medicine at the University of Heidelberg in Germany. He is also Head of Cardiology at two affiliated hospitals in the Heidelberg area. He is chairing the German Center for Cardiovascular Research Heidelberg/Mannheim (DZHK) and served as Speaker of the National Genome Research Network (NGFN). Prof. Katus was founder and director of the Academy of German Cardiac Society and is the now the Past-President of German Cardiac Society.
Professor Katus invented the cardiac troponin T assay, for which he holds a patent jointly with Roche Diagnostics. This invention changed practice of cardiology. In addition to his research interest in cardiac biomarkers he focused on molecular and genetic causes of cardiomyopathies and promoted in the translation of novel diagnostic and therapeutic strategies in heart failure. He is Co-Founder of InoCard GmbH, a company for the translation of molecular treatment strategies in cardiovascular diseases.
Professor Katus is member of the AHA, the ACC (German Chapter) the ESC and board member of the German Cardiac Society. He is co-editor of the Journal Clinical Research in Cardiology, which is the official scientific journal of the German Cardiology Society. He serves as reviewer for many national grant review committees suc as the British Heart Foundation, the Swiss “Herzfond” , the Agency National Francais, the Deutsche Forschungsgemeinschaft (DFG) and the Deutsche Herzstiftung.

 Watch the video

Christine Seidman

Christine Seidman is the Thomas W. Smith Professor of Medicine and Genetics at Harvard Medical School, an Investigator of the Howard Hughes Medical Institute, and Director of the Cardiovascular Genetics Service at Brigham and Women’s Hospital. She was an undergraduate at Harvard College and received a M.D. from George Washington University School of Medicine. Dr. Seidman served as an intern and resident in Internal Medicine at John Hopkins Hospital and received subspecialty training in cardiology at the Massachusetts General Hospital.

Dr. Seidman has pioneered the discovery of the genetic basis for heart muscle disorders, including hypertrophic and dilated cardiomyopathies and congenital heart disease. By engineering human mutations into iPSC-derived cardiomyocytes and mouse models she has identified molecular mechanisms and therapeutic targets. Her work has enabled development of clinical gene-based diagnostics, early and accurate identification of at-risk individuals, and pre-emptive interventions to limit the progression and devastating outcomes associated with these disorders.

Dr. Seidman is the recipient of the American Heart Association Basic Science Prize and Joseph A. Vita Award, the American Society for Clinical Investigation Award, the Pasarow Foundation Award in Cardiovascular Research, the Bristol-Myers Squibb Award for Distinguished Achievement in Cardiovascular Research and the Institut de France Fondation Lefoulon-Delalande Grand Prix for Science Award. She is a member of U.S. National Academy of Medicine and the National Academy of Science.

 Watch the video

ESC Gold Medal 2018

Marc Alan Pfeffer, M.D., Ph.D.

Dzau Professor of Medicine, Harvard Medical School
Senior Physician, Cardiovascular Division, Brigham and Women’s Hospital
Boston, MA, USA

Dr. Marc Pfeffer is the Dzau Professor of Medicine at Harvard Medical School, and Senior Physician in the Cardiovascular Division at the Brigham and Women’s Hospital in Boston. A noted researcher, Dr. Pfeffer, along with his late wife, Dr. Janice Pfeffer, and Eugene Braunwald MD, is credited with introducing the concept that angiotensin-converting enzyme inhibitors (ACEIs) could attenuate adverse ventricular remodelling following myocardial infarction and that this use would result in a prolongation of survival and other clinical benefits. Since this initial discovery, he has had a principal role in several practice-changing clinical trials such as SAVE, CARE, HEART, VALIANT, CHARM, PEACE, ARISE, TREAT, ALTITUDE, TOPCAT and ELIXA.

Dr. Pfeffer is considered as a team builder and takes pride in academic advancement of trainees and junior faculty collaborating on the trials. He is known for his fairness in data sharing and assisting others in developing meaningful scholarly works from study databases. He sets high standards for relationships with the sponsors whether industry or NHLBI.

Dr. Pfeffer serves on the Data Safety Monitoring Boards of major international trials. An internationally recognized expert in the field of cardiology, he was recognized by Science Watch as having the most ‘Hot Papers’ (highly cited) in all of clinical medicine. Dr. Pfeffer was listed as one of the highly influential biomedical researchers of 1996-2011 in the European Journal of Clinical Investigation. He is the recipient of the William Harvey Award of the American Society of Hypertension, the Okamoto Award from Japan’s Vascular Disease Research Foundation, the Clinical Research Prize, the James B. Herrick Award and was honored by the Distinguished Scientist Award from both the American Heart Association as well as the American College of Cardiology, and the Lifetime Achievement Award from both the Heart Failure Society of America and the Heart Failure Association of the European Congress of Cardiology. Dr. Pfeffer is an Honorary Fellow of the Royal College of Physicians and Surgeons of Glasgow and is the recipient of an Honorary Doctoral Degree from Sahlgrenska Academy, University of Gothenburg, Sweden.

Evgeny V. Shlyakhto

Director of the Almazov Centre, Russia

Professor Evgeny Shlyakhto, Director General of the Almazov National Medical Research Centre, Academician of the Russian Academy of Science, President of the Russian Society of Cardiology, Fellow of the European Society of Cardiology, the American Heart Association, and the American College of Cardiology.

Professor Shlyakhto was born on June 29, 1954 in Pogar, the Bryansk region. He graduated from the Pavlov Medical University in Saint Petersburg in 1977 and became Doctor of Science in Medicine in 1992, Professor in 1994, Honored Russian Scientist in 2004, and Academician of the Russian Academy of Sciences in 2014.

Evgeny Shlyakhto has been the Director General of the Almazov National Medical Research Centre since 2001 and the President of the Russian Society of Cardiology since 2011. In 2010, he became a member of the WHO Expert Working Group.

The Centre led by Prof. Shlyakhto carries out intensive research in the fields of translational medicine, molecular diagnostics, development of diagnostic tools for personalized treatment, cellular and tissue engineering for therapeutic purposes, creation of biocompatible materials and tissue-engineered constructs designed to create breakthrough medical technologies of fundamental importance for providing high-tech care to patients with cardiovascular, endocrine and blood diseases.

The results of research work by Prof. Shlyakhto have been summarized in more than 800 publications, 16 inventions, 2 scientific discoveries, and a number of monographs. Prof. Shlyakhto was a supervisor in 57 PhD and 20 DSc students..

Professor Shlyakhto is a member of the Presidium of the Russian Academy of Science, the Presidential Council for Science and Education, the Regional Health Council under the Federation Council of the Russian Federal Assembly, the Expert Health Council of the Federation Council Committee on Social Policy of the Russian Federal Assembly, Vice President of the National Medical Chamber.

Evgeny Shlyakhto is the Editor-in-Chief of the following medical journals: Russian Journal of Cardiology, Translational Medicine, and Journal of Arrhythmology. He also is a member of the international editorial board of the European Heart Journal.

Professor Shlyakhto plays an active role in such international committees as the ESC Congress Programme Committee (since 2012) and of the ESC Committee for Practice Guidelines (since 2015).

Evgeny Shlyakhto received the Russian Federation Government Prize in science and technology in 2009 and won the Pavlov Award, the prize for scientific and technological achievement in Physiology and Medicine from the Saint Petersburg Government and St. Petersburg Scientific Center of the Russian Academy of Sciences, in 2011. He received an Order of Honour in 2012 and 4th class Order of Merit for the Motherland in 2017.

Ottavio Alfieri, MD

Professor of Cardiac Surgery
S. Raffaele University Hospital in Milan, Italy

In the initial part of his career he was devoted to the treatment of congenital heart diseases, first in Bergamo, Italy and then in USA, as Clinical Fellow at the Children’s Hospital of Buffalo, NY and as a Research Fellow at the University of Alabama in Birmingham.
His experience with adult cardiac surgery started in 1980 at the St. Antonius Hospital in Neuwegein, NL, where he spent six years as member of the staff.

He came back to Italy in 1986 to become Chief Surgeon at the Ospedali Civili in Brescia. Ten years later he moved to Milan as Professor and Chairman of Cardiac Surgery at San Raffaele University Hospital.

He is author or co-author of more than 600 peer-reviewed papers, related to many areas of cardiac surgery.
He is member of the editorial board of several scientific journals.

His main interest is surgery for valvular heart disease (particularly mitral valve repair).

In the early ‘90s he originally developed the Edge-to-Edge technique, a method of mitral valve repair which is the basis of the currently most used type of percutaneous correction of mitral regurgitation.

During the last 15 years he has been very active in favouring in his department the multidisciplinary approach in the treatment of cardiac diseases. Particularly he was able to introduce transcatheter technologies in the daily cardiac surgical practice.

In 2011, he served as President of the European Association of Cardio-Thoracic Surgery (EACTS).
He is currently member of the ESC, EACTS, AATS, STS.

He is now President of the “Alfieri Heart Foundation” created to support research and innovation at the San Raffaele University Hospital.

ESC Gold Medal 2017

W Wijns, FESC (Brussels, BE)

Hear about his professional journey & scientific experiences. 
What made him do it? What lessons has he learned? And what may inspire you?

In recent years Professor Wijns has held board memberships in the European Society of Cardiology and the World Heart Federation. He is currently Chairman of PCR, co-Director of Africa PCR and EuroPCR, the official congress of the European Association of Percutaneous Cardiovascular Interventions.

Professor Wijns previously worked at the Thorax Center in Rotterdam, where he was actively involved with the first applications of nuclear cardiology, thrombolysis and coronary dilatation, and the University of Louvain in Brussels, where he was Clinical Professor of Cardiology.

Professor Wijns’ research focuses on heart attacks and sudden death caused by unexpected blockage of arteries supplying the heart with blood and oxygen. 

A DeMaria (La Jolla, US)

Anthony N. DeMaria received his M.D. from the New Jersey College of Medicine in 1968. He did his medical residency at the United States Public Health Service Hospital in Staten Island, New York. In 1981, he accepted the position as Chief of Cardiology at the University of Kentucky in Lexington, Kentucky.  In 2004 he founded the UCSD Sulpizio Family Cardiovascular Center. His field of specialization is cardiac imaging techniques, particularly echocardiography (ultrasound of the heart).

Dr. DeMaria is a Diplomat in the American Board of Internal Medicine and is board certified by the Subspecialty Board in Cardiovascular Disease. He is Past President of the American College of Cardiology and Past President of the American Society of Echocardiography. He has served as a member of the Subspecialty Board on Cardiovascular Disease of the American Board of Internal Medicine and Chair of the Diagnostic Radiology Study Section of the National Institutes of Health. He holds memberships in numerous professional organizations, including the American Heart Association, the American Federation for Clinical Research and the Association of University Cardiologists.

Dr. DeMaria served as the Editor-in-Chief of the Journal of the American College of Cardiology from 2002-2014, and he has served as an editorial consultant and member of various other editorial boards. He has authored or co-authored over 700 articles for medical journals. Dr. DeMaria is listed in the Best Doctors in America and by Good Housekeeping as Best Heart Doctors in America.

ESC Gold Medal 2016

This year, two ESC Gold Medallists receive ESC honours:

Dr. Bernard Gersh and Prof. Alain Cribier.

Dr. Bernard Gersh

Dr. Gersh is Professor of Medicine at the Mayo Clinic College of Medicine having received his undergraduate degree at the University of Cape Town and obtaining a D.Phil at Oxford University.  He also has an Honorary PhD from the University of Coimbra, Portugal.  He has published approximately 880 manuscripts, 140 book chapters, and has edited 15 books.  He has served on multiple editorial boards and is currently Deputy Editor of the European Heart Journal.  Prior awards include the Silver Medal of the European Society of Cardiology, the James B. Herrick Award, the Distinguished Achievement Award of the American Heart Association, Master of the American College of Cardiology, and the Hatter Award for the Advancement of Cardiovascular Science from the University College London and the University of Cape Town.  Dr. Gersh is the 2015 recipient of the Mayo Clinic Distinguished Alumni Award.

Prof. Alain Cribier

Prof. Alain Cribier, MD, has been for 20 years Chief of Cardiology at the University Hospital Charles Nicolle of Rouen, France. He became widely recognized for having developed new interventional technologies for the treatment of valvular heart diseases: Balloon Aortic Valvuloplasty in 1985, Mitral Commissurotomy in 1994, and after 15 years of research the Transcatheter Implantation of Aortic Valves (TAVI), performing the first world case in Rouen in 2002. This last breakthrough technology which is now widely used in the world with more than 300 000 patients treated and an explosive growth will have a durable impact on the pattern of medical practice. Prof Cribier has received a number of prestigious scientific distinctions and awards for his pioneering work. He has published more than 600 indexed articles in the fields of interventional cardiology, valve disease and innovative technologies. 

ESC Gold Medal 2015

This year, three ESC Gold Medallists receive ESC honours:

Professor Keith Fox, Professor Michel Haissaguerre and Professor Richard Popp

Professor Keith Fox

ESC: Professor Fox, you have a long association with the ESC. How did it all start?

KF: I was one of the founding Fellows of the ESC back in the 1990s and since then have been responsible for several studies in acute coronary syndromes and thrombosis, with key results incorporated into European guidelines. Some of our results from the GRACE study, for example, have provided strong evidence on risk assessment and its timing in acute coronary syndromes. At a more formal level I was a board member of the ESC from 2008 to 2010 and from 2012 to 2014, and also Chair of the Scientific & Clinical Programme Committee for the ESC. Last year there were more than 30,000 taking part and a record number of abstracts submitted. That’s plenty of work for the Programme Committee!

And your principal scientific and clinical interests?

Acute coronary diseases and atherothrombosis - in fact, the whole pathway from plaque formation to clinical manifestations. So this has involved me in studies of disease mechanisms in ACS to the assessment of antiplatelet and anticoagulant therapies. Presently, we are looking at the influence of genes and inflammation on plaque rupture events.

Which of these studies are you most proud of?

Well it’s difficult to say. They seem to have happened in a series of chapters, starting with our first studies on tPA in St Louis. But I guess I must be most proud of those whose outcomes have been implemented into guidelines and everyday practice in ACS. So to that extent I’d note our studies from the GRACE registry programme, and the RITA, ROCKET-AF and OASIS programmes. The RITA-3 trial in 2005, for example, compared a strategy of routine angiography and revascularisation in non-STE ACS patients with a non-intervention strategy of watchful management. There was uncertainty about this at the time, but our results over five years clearly showed the benefit of routine intervention. So now, for higher risk patients we adopt a routine strategy of early angiography and intervention. More recently we’ve updated the algorithms derived from the GRACE registry data into a simple web-based and app risk calculator. The original risk prediction model was based on outcomes from more than 100,000 ACS patients, and now the risk scores we calculated have been validated externally and prospectively.

What does an ESC gold medal mean to you?

Of course, I feel very honoured, but also a little embarrassed to be in such company. My contributions to cardiology and the ESC seem somewhat modest alongside those of other gold medallists, but it s a great honour and one that I feel very proud of and very grateful for.

Professor Michel Haissaguerre

ESC: How did you first become interested in cardiology?

MH: Initially, I decided to study medicine because I was interested in psychology. But during my second year internship with Professor Jean Francois Warin in Bordeaux I became fascinated by the way 12-lead ECG traces could describe an invisible electrical mechanism operating within the heart.

What have been your main research interests?

Once simple arrhythmias became, in the words of Douglas Zipes, ‘an endangered species’, the last big hurdle to overcome was cardiac fibrillation. My research team’s contribution has been to demonstrate that these chaotic wavelets have discrete origins, with the igniting sparks located mostly in the pulmonary veins in the atria or Purkinje cells in the ventricles.

How did radio ablation for atrial fibrillation come about?

With Pierre Jais, Mélèze Hocini, Dipen Shah and others I began mapping the first premature beat that initiates fibrillation. We found the sources of AF were not in the atria, but fired from cells in the pulmonary veins located in the vascular wall. It took about four years to be sure of our results – 99% perspiration for 1% inspiration. Now over 300,000 patients have been treated by targeting the pulmonary veins.

Have you done the same for VF?

The same mapping concept was performed for patients with repetitive VF, but proved challenging because of the rapid syncopal nature of VF and isolated runs of ventricular ectopies. We found Purkinje sources initiating VF in both normal hearts and nearly all types of cardiac disease, with confirmation by discrete successful ablation. Such findings could have large therapeutic implications.

What does your new institute hope to achieve?

In 2012 we established the LIRYC Electrophysiology and Heart Modelling Institute in Bordeaux to develop a multidisciplinary programme dedicated to cardiac electrical dysfunctions such as AF, ventricular tachyarrhythmias and electrical ventricular dyssynchrony leading to heart failure using high-resolution mapping, cardiac imaging, signal processing and computer modelling. The institute brings together over 150 practitioners with multiple specialties in electrophysiology - from ion channels to whole heart and patient care.

What are your future research goals?

While we’ve made progress in understanding arrhythmia mechanisms, the identification of risk factors, genetic abnormalities and tissue biomarkers needs to be improved. We need to be able to recognise those individuals who are susceptible to VF and sudden death. Advances will hopefully help optimise screening and therapeutic protocols and reduce the burden of arrhythmic morbidity and mortality.

Professor Richard L Popp

ESC: What first attracted you to cardiology?

RLP: The cardiac physical exam was the most fascinating thing I could imagine - I had always wanted to understand how the heart worked both normally and under the influence of disease.

Who have been your most influential mentors and how did they help your career development?

J. Michael Criley from Johns Hopkins got me involved in angiography and Harvey Feigenbaum from Indiana University was one of the first in the US to use ultrasound for cardiac imaging. I’d also like to acknowledge over 150 dedicated cardiology fellows who taught me an enormous amount and pushed me to answer their challenging questions.

What do you regard as your greatest clinical and or scientific achievement?

I was privileged to be part of the development of virtually all aspects of ultrasound cardiac diagnosis. My work was developing non-invasive ways to measure left ventricular volume, stroke volume and ejection fraction - and establishing standards for examination and measurement methods in echocardiography. With Liv Hatle I helped develop Doppler methods to measure gradients across heart valves and methods to recognise diastolic ventricular dysfunction. But one of my greatest achievements has been my involvement in the careers of a large number of leading academic cardiologists including Fausto Pinto and Jos Roelandt.

What do you regard as the most significant development in your field of cardiology over the last 20 years?

The fact that non-invasive methods have replaced invasive cardiac catheterisation for assessing structural heart disease is a major advance for patients allowing serial monitoring of the natural course of valve disease and heart failure.

Looking into a crystal ball how do you see your field developing?

Use of personal hand-held inexpensive ultrasound imaging devices will have a big role to play in augmenting physical exams. I believe that hand-held ultrasound units, the size of a cell phone, will ultimately replace the stethoscope.

What advice would you give to young cardiologists?

Providing ‘patient centered care’ with a team of healthcare providers should be your focus. Training to do everything the team can provide will not serve either you or the patient well.

How have you achieved a work life balance?

I have been incredibly lucky to have a wonderful wife Janis, two sons and five grandchildren. While you can always get someone to cover your patients, no one else can cover your role as a spouse or parent.

Previous ESC Gold Medal award winners

ESC Gold Medal 2014

• Professor Petr Widimský
• Professor Sir Rory Collins
• Professor Alain Carpentier

ESC Gold Medal 2013

• Evgeny Chazov
• Douglas Zipes

ESC Gold Medal 2012

• Pedro Brugada
• Patrick Serruys
• Ryozo Nagai

ESC Gold Medal 2011

• Henri Kulbertus
• Jean Claude Daubert
• Peter Libby

ESC Gold Medal 2010

• Peter Sleight
• Christian Cabrol
• Lars Wallentin

ESC Gold Medal 2009

• Luigi Tavazzi
• Frans Van de Werf
• Shahbudin Rahimtoola

ESC Gold Medal 2008

• John Martin
• Jane Somerville
• Salim Yusuf

ESC Gold Medal 2007

• Valentine Fuster
• Karl Swedberg

ESC Gold Medal 1968 - 2006

Pavel LUKL
ESC President 1968 – 1972

Herman SNELLEN
ESC President 1972 – 1976

Henri DENOLIN
ESC President 1976 – 1980

Franz LOOGEN
ESC President 1980 – 1984

Paul HUGENHOLTZ
ESC President 1984 – 1988

Hans-Peter KRAYENBÜHL
ESC President 1988 – 1990

Michel BERTRAND
ESC President 1991 – 1994

Sigurd NITTER-HAUGE
Chairman Executive Scientific Committee 1991 – 1994

Philip POOLE-WILSON
ESC President 1994 – 1996

Günter BREITHARDT
ESC President 1996 – 1998

Desmond JULIAN
1998

AMERICAN COLLEGE OF CARDIOLOGY
1999

Wil NEIJMANN
2000

Sir Richard DOLL
2000

Kalevi PYÖRÄLÄ
2000

Lars RYDÉN
ESC President 1998-2000

Henrick Joan Joost WELLENS
2002 

Attilio MASERI
2002

Michiel J. JANSE
2002
Editor in Chief Cardiovascular Research 1994 – 2002

Maarten L. SIMOONS
ESC President 2000-2002

Liv HATLE
2003

Martin MICHEÁL
2004

Eugene BRAUNWALD
2004

Jean-Pierre BASSAND
ESC President 2002-2004

A John CAMM
2005

Michal TENDERA
ESC President 2004-2006

Sir Magdi YACOUB
2006

Kim FOX
ESC President 2006-2008

Roberto FERRARI
ESC President 2008-2010

Fausto PINTO
ESC President 2014-2016